Trial Profile
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf and Myfortic.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin; Daclizumab; Mycophenolate sodium
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 14 Aug 2010 New trial record